|
KMID : 1151620210060020145
|
|
Journal of Retina
2021 Volume.6 No. 2 p.145 ~ p.149
|
|
|
Short-term Efficacy of Brolucizumab Injection for Neovascular Age-related Macular Degeneration with Limited Response to Aflibercept
|
|
Kim Jae-Hui
|
|
|
Abstract
|
|
|
Purpose: To evaluate short-term efficacy of brolucizumab injection for neovascular age-related macular degeneration (nAMD) refractory to aflibercept.
Case summary: A 66-year-old woman was diagnosed with nAMD and treated with aflibercept. At diagnosis, visual acuity was 0.2 and central retinal thickness (CRT) was 485 μm. After three injections of aflibercept, retinal edema was resolved. However, 3 months after the last injection, recurrence was noted. The patient was treated with aflibercept or bevacizumab for 20 months. However, intraretinal edema was not resolved despite treatment. The patient was switched to brolucizumab, at which time, visual acuity was 0.2 and CRT was 424 μm. Two weeks after switching to brolucizumab, intraretinal fluid was decreased markedly with CRT reduced to 348 μm and visual acuity improved to 0.3. Four weeks after switching, CRT was maintained at 354 μm. No complication, such as intraocular inflammation or occlusive retinal vasculitis, was noted.
Conclusions: Switching to brolucizumab was found to be beneficial in reducing retinal thickness in nAMD refractory to aflibercept.
|
|
|
KEYWORD
|
|
|
Aflibercept, Age related macular degeneration, Brolucizumab, Choroidal neovascularization
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|